Development and therapeutic potential of DNA-dependent protein kinase inhibitors

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The DNA damage response (DDR) pathway is essential for maintaining genomic stability.
• Cancer cells exhibit increased genomic instability, presenting a therapeutic vulnerability.
• DNA-dependent protein kinase (DNA-PK) is a key enzyme in the non-homologous end joining (NHEJ) pathway for repairing DNA double-strand breaks (DSBs).

Purpose of the Study:

• To review the structural aspects of DNA-PK and associated proteins.
• To elaborate on the development and structure-activity relationships (SARs) of DNA-PK inhibitors.
• To discuss recent advancements in the clinical applications of DNA-PK inhibitors for cancer therapy.

Main Methods:

• Literature review focusing on DNA-PK structure, inhibitor development, and clinical trials.
• Analysis of structure-activity relationships (SARs) for various DNA-PK inhibitor scaffolds.
• Synthesis of information on the therapeutic potential of targeting the DDR pathway in cancer.

Main Results:

• DNA-PK is a critical target for cancer therapy due to its role in DSB repair.
• Diverse scaffolds have been explored for developing potent and selective DNA-PK inhibitors.
• Several DNA-PK inhibitors are progressing through clinical trials, showing therapeutic promise.

Conclusions:

• Inhibiting DNA-PK represents a viable strategy for selective cancer cell killing by exploiting their inherent genomic instability.
• Understanding SARs is crucial for designing next-generation DNA-PK inhibitors.
• Further research and clinical evaluation are warranted to fully realize the potential of DNA-PK inhibitors in oncology.